An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Updates from AMA House of Delegates 2023 Interim Meeting
Last month, the ACR’s delegation to the AMA House of Delegates discussed and advanced resolutions to address specialty workforce shortages, payment reform and access to care.
Remote Prescribing Exceptions Extended Through 2024
The Department of Health & Human Services and Drug Enforcement Administration have extended through Dec. 31, 2024, exceptions that allow providers to prescribe controlled medications via telemedicine appointments without conducting an in-person evaluation.
Experts Highlight Key Issues Impairing Access to Care
Speakers discussed common payer practices and policies that rheumatologists must navigate to secure and maintain appropriate care for their patients, including pharmacy benefit managers and prior authorization.
Research & Precision Medicine in Community Rheumatology Practices
Rheumatologists in community practices don’t have to abandon their research interests. The Rheumatologist recently interviewed three community practice rheumatologists from around the U.S. to find out their approaches to patient management, staffing and other areas of the practice. Here, they discuss their approach to incorporating research into their practice. At New England Rheumatology & Osteoporosis,…
Heterogeneity in Lupus: Lessons from the Autoimmune Centers of Excellence
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
Get AMPed: Understanding RA Through the Accelerating Medicines Partnership
SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…
Brains & Brawn: Exciting Developments in Our Understanding of Myositis
SAN DIEGO—The inflammatory myopathies are a heterogeneous group of conditions that, although discovered decades ago, continue to challenge rheumatologists in terms of their myriad clinical presentations. In Flexing Strong Science on Weak Muscles: Genetics, Genomics and Autoantibodies in Myositis, two speakers provided exceptionally helpful insights into these conditions, using novel tools for analysis. 6 Types…
Old Disease, New Tricks: A Novel Approach to Understanding Gout
SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…
Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology
SAN DIEGO—At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 325
- Next Page »